Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, U.S.A.
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Clin Sci (Lond). 2018 Jan 11;132(1):85-91. doi: 10.1042/CS20171090. Print 2018 Jan 16.
Accumulating evidence supports a relationship between the complexity and diversity of the gut microbiota and host diseases. In addition to alterations in the gut microbial composition, the metabolic potential of gut microbiota has been identified as a contributing factor in the development of diseases. Recent technological developments of molecular and biochemical analyses enable us to detect and characterize the gut microbiota via assessment and classification of its genomes and corresponding metabolites. These advances have provided emerging data supporting the role of gut microbiota in various physiological activities including host metabolism, neurological development, energy homeostasis, and immune regulation. Although few human studies have looked into the causative associations and underlying pathophysiology of the gut microbiota and host disease, a growing body of preclinical and clinical evidence supports the theory that the gut microbiota and its metabolites have the potential to be a novel therapeutic and preventative target for cardiovascular and metabolic diseases. In this review, we highlight the interplay between the gut microbiota and its metabolites, and the development and progression of hypertension, heart failure, and chronic kidney disease.
越来越多的证据支持肠道微生物群落的复杂性和多样性与宿主疾病之间存在关联。除了肠道微生物组成的改变外，肠道微生物群落的代谢潜能也被认为是疾病发展的一个因素。最近分子和生化分析技术的发展使我们能够通过评估和分类其基因组和相应的代谢物来检测和描述肠道微生物群落。这些进展提供了支持肠道微生物群在包括宿主代谢、神经发育、能量平衡和免疫调节在内的各种生理活动中发挥作用的新兴数据。尽管少数人类研究探讨了肠道微生物群与宿主疾病之间的因果关联和潜在病理生理学，但越来越多的临床前和临床证据支持这样一种理论，即肠道微生物群及其代谢产物有可能成为心血管和代谢疾病的新的治疗和预防靶点。在这篇综述中，我们强调了肠道微生物群落及其代谢产物之间的相互作用，以及它们与高血压、心力衰竭和慢性肾病的发生和发展之间的关系。
